WTC
BBIO icon

WhitTier Trust Company’s BridgeBio Pharma BBIO Stock Holding History

WhitTier Trust Company’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.48K Buy
96
+61
+174% +$4.27K ﹤0.01% 1112
2026
Q1 		$2.53K Buy
+35
New +$2.54K ﹤0.01% 1241

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

WhitTier Trust Company's BBIO Position: Q2 2026 in Review

WhitTier Trust Company increased its BridgeBio Pharma (BBIO) stake by 174% in Q2 2026, buying an estimated $4.27K and bringing the position to 96 shares worth $7.48K. The position accounts for ﹤0.01% of the portfolio, ranked #1112.

WhitTier Trust Company first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • WhitTier Trust Company held 96 shares of BridgeBio Pharma worth $7.48K as of Q2 2026.
  • WhitTier Trust Company bought 61 BridgeBio Pharma shares in Q2 2026, an estimated $4.27K.
  • BridgeBio Pharma made up ﹤0.01% of WhitTier Trust Company's portfolio in Q2 2026, its #1112 holding.
  • WhitTier Trust Company first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on WhitTier Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.